Investors Purchase High Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) was the recipient of unusually large options trading activity on Wednesday. Traders acquired 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical daily volume of 53 put options.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Massachusetts Financial Services Co. MA lifted its position in Maravai LifeSciences by 11.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 14,150,891 shares of the company’s stock worth $361,273,000 after acquiring an additional 1,459,720 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in Maravai LifeSciences by 141.4% during the 4th quarter. Thrivent Financial for Lutherans now owns 6,178,115 shares of the company’s stock worth $88,409,000 after acquiring an additional 3,618,369 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Maravai LifeSciences by 9.1% during the 4th quarter. JPMorgan Chase & Co. now owns 3,911,032 shares of the company’s stock worth $55,967,000 after acquiring an additional 326,260 shares during the last quarter. Renaissance Technologies LLC lifted its position in Maravai LifeSciences by 118.5% during the 4th quarter. Renaissance Technologies LLC now owns 3,326,948 shares of the company’s stock worth $47,609,000 after acquiring an additional 1,804,248 shares during the last quarter. Finally, Clearbridge Investments LLC lifted its position in Maravai LifeSciences by 7.5% during the 4th quarter. Clearbridge Investments LLC now owns 3,198,111 shares of the company’s stock worth $45,765,000 after acquiring an additional 222,376 shares during the last quarter. Institutional investors and hedge funds own 48.67% of the company’s stock.

Maravai LifeSciences Stock Up 1.4 %

MRVI stock opened at $15.57 on Thursday. The company has a current ratio of 7.70, a quick ratio of 7.31 and a debt-to-equity ratio of 0.58. Maravai LifeSciences has a 1 year low of $12.16 and a 1 year high of $41.82. The company has a fifty day simple moving average of $14.38 and a 200 day simple moving average of $16.83. The firm has a market cap of $3.97 billion, a PE ratio of 9.44 and a beta of -0.22.

Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.01. Maravai LifeSciences had a net margin of 24.94% and a return on equity of 57.88%. The business had revenue of $204.70 million during the quarter, compared to analyst estimates of $204.95 million. During the same quarter in the previous year, the business earned $0.45 EPS. Maravai LifeSciences’s quarterly revenue was down 10.4% compared to the same quarter last year. Sell-side analysts anticipate that Maravai LifeSciences will post 0.35 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on MRVI. Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $25.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, February 23rd. Credit Suisse Group lowered their price target on shares of Maravai LifeSciences from $26.00 to $23.00 and set an “outperform” rating on the stock in a report on Thursday, February 23rd. Royal Bank of Canada started coverage on shares of Maravai LifeSciences in a report on Tuesday, December 6th. They set an “outperform” rating and a $22.00 price target on the stock. The Goldman Sachs Group lowered their price target on shares of Maravai LifeSciences from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, January 17th. Finally, UBS Group cut shares of Maravai LifeSciences from a “buy” rating to a “neutral” rating and lowered their price target for the company from $20.00 to $16.00 in a report on Thursday, January 5th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.56.

Maravai LifeSciences Company Profile

(Get Rating)

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.